Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists Article Report uri icon


MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Brain Neoplasms
  • Glioblastoma


  • Peroxisome proliferator-activated receptors (PPAR) are members of a superfamily of nuclear hormone receptors. Activation of PPAR isoforms elicits both antineoplastic and anti-inflammatory effects in several types of mammalian cells. PPARs are ligand-activated transcription factors and have a subfamily of three different isoforms: PPAR alpha, PPAR gamma, and PPAR beta/delta. All isoforms heterodimerise with the 9-cis-retinoic acid receptor RXR, and play an important part in the regulation of several metabolic pathways, including lipid biosynthesis and glucose metabolism. Endogenous ligands of PPAR gamma include long-chain polyunsaturated fatty acids, eicosanoid derivates, and oxidised lipids. Newly developed synthetic ligands include thiazolidinediones-a group of potent PPAR gamma agonists and antidiabetic agents. Here, we review PPAR gamma-induced antineoplastic signalling pathways, and summarise the antineoplastic effects of PPAR gamma agonists in different cancer cell lines, animal models, and clinical trials.

publication date

  • July 2004



  • Report


Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(04)01509-8

PubMed ID

  • 15231248

Additional Document Info

start page

  • 419

end page

  • 29


  • 5


  • 7